// App-Quantinova.ai

3020 : Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study and Preliminary Results of a Single-Arm Extension

Researchers

Presenter

  • Laurie H. Sehn

Principal Investigators

  • Mark Hertzberg

  • Stephen Opat

  • Alex F. Herrera

  • Sarit E Assouline

  • Christopher Flowers

  • Tae Min Kim

  • Andrew McMillan

  • Muhit Ozcan

  • Violaine Safar

  • Gilles Salles

  • Lisa Musick

  • Jamie Hirata

  • YiMeng Chang

  • Grace Ku

  • Matthew J Matasar

Medical Centers

  • BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, BC, Canada

  • Prince of Wales Hospital and University of New South Wales,Sydney, NSW,Australie

  • Clinical Haematology, Monash Health and Monash University, Clayton, Australia

  • City of Hope, Duarte, CA

  • Division of Hematology,Sir Mortimer B. Davis-Jewish General Hospital, Department of Oncology, McGill University,Montreal, QC,Canada

  • 1.MD Anderson Cancer Center, Houston, TX

  • Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, United Kingdom

  • Ankara University School of Medicine, Pharmacology, Ankara, Turkey

  • GINECO & Centre Hospitalier Lyon-Sud, Lyon, France

  • Roche/Genentech, South San Francisco, CA

  • Genentech, Inc., South San Francisico, CA

  • Hoffmann-La Roche Ltd, Mississauga, ON, Canada

  • Department of Medicine, Lymphoma Service, Memorial Sloan-Kettering Cancer Center/New York Presbyterian, New York, NY

Locations

  • Canada

  • Australia

  • United States

  • Republic of South Korea

  • United Kingdom

  • Turkey

  • France

Companies

  • Genentech, Inc.

  • F. Hoffmann-La Roche

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • Peripheral neuropathy

  • B cell lymphomas

  • Lymphomas

Biomarkers

  • Plasma Renin Activity

Drug/Treatment

  • Polatuzumab vedotin

  • Bendamustine

  • Rituximab

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Single Arm

  • Cohort

Phase

  • I

Study Id's

  • NCT02257567

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved